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Abstract 41 
 42 
There is conflicting results on whether prior antiplatelet therapy (APT) is associated with poor 43 
outcome in spontaneous intracerebral haemorrhage (ICH) patients. To determine whether 44 
prior APT is associated with spontaneous ICH, and whether there is a difference between the 45 
different types of APT, including cyclooxygenase inhibitor (COX-I), adenosine diphosphate 46 
receptor inhibitor (ADP-I), and phosphodiesterase inhibitor (PDE-I). A retrospective study of 47 
patients with ICH diagnosed between 2001 and 2013 in the National Health Insurance 48 
Research Database. Baseline unbalance between APT and non-APT groups was solved by 49 
multivariable adjustment (primary analysis) and propensity score matching (sensitivity 50 
analysis). Patients with prior APT had a higher rate of in-hospital death (odds ratio [OR], 1.16; 51 
95% confidence interval [CI], 1.09–1.23) compared to non-APT group. Compared to non-APT 52 
group, there was a greater rate of in-hospital death with spontaneous ICH with ADP-I (OR, 53 
1.49; 95% CI, 1.24–1.79), and COX-I (OR, 1.17; 95% CI, 1.09–1.25). PDE-I exhibited no 54 
difference in in-hospital death with spontaneous ICH (OR, 1.03; 95% CI, 0.91–1.16) compared 55 
to non-APT group. Remarkably, the in-hospital mortality rate was significantly higher in the 56 
ADP-I group than in the PDE-I group (hazard ratio, 1.45; 95% CI, 1.17–1.80). In this study, ADP-57 
I and COX-1, but not PDE-I is the most likely contributors to the association of APT with poor 58 
outcome with spontaneous ICH patients. These findings suggest the complexity of the 59 
different mechanism of actions of prior APT can alter the outcome in spontaneous ICH. 60 
  61 
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Introduction  62 
 63 
Platelets are essential for normal haemostasis, but can also be involved in thrombosis. 64 
Antiplatelet therapy (APT) has recently gained popularity due to its reported beneficial effects 65 
in cardiovascular and cerebrovascular diseases. However, platelet dysfunction as measured 66 
by platelet function assays has been associated with hematoma expansion and worse clinical 67 
outcome [1]. 68 
 69 
Recent studies have suggested that there is a higher risk factor for intracerebral haemorrhage 70 
(ICH) patients under APT treatment associated with poor clinical outcome in the setting of 71 
both spontaneous [2] as well as traumatic ICH [3, 4]. Furthermore, several studies have 72 
revealed higher rates of progression of initial ICH in patients on APT [5]. However, the 73 
association of APT with ICH outcome from these studies remains controversial, possibly due 74 
to differences in sample size, demographics, methodology, and statistical analysis [6, 7] 75 
 76 
Interestingly, given there are several forms of APT, few studies have investigated the type of 77 
antiplatelet agents to the clinical outcomes. Studies assessing the impact of APT in this cohort 78 
of patients generally have grouped all the antiplatelet mediations into one group without 79 
considering the different types of antiplatelet medications. However, the different 80 
mechanism of action of the different antiplatelet agents may cause variable outcomes. 81 
Therefore, we proposed to study the association of prior use of different groups of APT on 82 
patients with ICH in a real world setting, using Taiwan’s National Health Insurance Research 83 
Database (NHIRD).  84 
 85 
  86 
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Methods 87 
Data source 88 
A nationwide population-based cohort study using Taiwan’s National Health Insurance 89 
Research Database (NHIRD) was conducted. It consisted of standard computerized claims 90 
document that covers nearly 100% of the 23.7 million residents of Taiwan [8]. This is a 91 
comprehensive health-related database for each patient include demographic characteristics, 92 
medical diagnoses, surgical procedure, blood transfusion, and details of all prescriptions. 93 
Accuracy and validation of NHIRD data are based on regular auditing claims by the National 94 
Health Insurance Bureau. Personal identities have been encrypted for privacy protection, but 95 
all data sets could be linked with anonymous identifiers created for research purpose. 96 
Therefore, the study was completely exempt from ethics review by the ethics institutional 97 
review board of Chang Gung Memorial Hospital (Taiwan). 98 
Study population 99 
In this study, eligible patients was screened from hospitalization records by principal diagnosis, 100 
which was recorded according to the International Classification of Disease, Ninth Revision, 101 
Clinical Modification (ICD-9 CM) codes. Eligible patients from the NHIRD were identified as 102 
those admitted for first event of cerebrovascular accident from January 1, 2001 and December 103 
31, 2013 (ICD-9 CM codes, 430–437) (Supplemental Table 1). Within this cohort of patients 104 
with cerebrovascular accident, we excluded patients with incomplete medical record and 105 
were admitted without the diagnosis of spontaneous intracerebral haemorrhage (ICH).  We 106 
also excluded the comorbidities where the conditions can possibly interfere with coagulation 107 
conditions, such as coagulopathy, liver cirrhosis, malignancy and autoimmune disease 108 
predating the index date. In order to compare the effect of different type single antiplatelet 109 
regiment on ICH patients, we retrieved the patient's claim data from outpatient clinics or 110 
refilling prescription at pharmacies 3 months before the index admission. According to 111 
prescription record system, we excluded the patients who were under anticoagulant or with 112 
combined APT treatment. Overall, 97,335 patients with ICH qualified for this study.  113 
Exposure of antithrombotic therapy 114 
The study population was divided into APT and non-APT groups according to prescription 115 
record system. According to different pharmacological effect of antiplatelet agents, eligible 116 
patients were further divided into three groups (i) irreversible cyclooxygenase inhibitors (COX-117 
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I): Aspirin, (ii) Adenosine diphosphate receptor inhibitor (ADP-I): clopidorgrel or ticlopidine, 118 
(iii) Phosphodiesterase inhibitor (PDE-I): dipyridamole or cilostazol.  119 
Comorbidities and outcome measurement 120 
We extracted the baseline patient’s characteristics, including gender age, hospital level, 121 
monthly income, and urbanization level. We also obtained medical records before the index 122 
admission to track their history of comorbidities and major events. Charlson comorbidity 123 
index (CCI) scores were used to determinate overall systemic health [9]. Estimated National 124 
Institute of Health Stroke Scale (NIHSS) was applied to access the severity of haemorrhagic 125 
stroke, which was validated in a previous NHIRD study [10]. To identify neurosurgical 126 
procedures and in-hospital events, ICD-9-CM and NHI reimbursement codes during the index 127 
hospitalization were used. Accuracy of ICD-9-CM, NHI reimbursement codes and identification 128 
of comorbidity of NHIRD have been validated in patients with cerebrovascular events [11, 12]. 129 
The outcomes of interest in this study included antiplatelet related complication, in-hospital 130 
mortality, and long-term outcome including all-cause mortality, recurrent ICH and ischemic 131 
stroke within 6 months after the index hospitalization. Patients were followed from their index 132 
admission date to date of event occurrence, or December 31 2013, or death. 133 
Statistical analysis 134 
Risks of in-hospital outcomes among the study groups were compared using logistic 135 
regression analyses. Risks of time to event outcomes during a 6-month follow up among 136 
groups were compared using Cox proportional hazard models. The regression analyses were 137 
adjusted for all the covariates, including sex, age, hospital level, income and urbanization level, 138 
seven coexisting diseases, prior ischemic stroke, prior myocardial infarction and stroke 139 
severity index via NIHSS, four neurosurgical procedures during the index hospitalization, and 140 
the index year. There were seven pairwise comparisons among the study groups (APT vs. Non-141 
APT; and the six pairwise comparisons among the non-APT and different APT groups), 142 
therefore to avoid type 1 errors,  a Bonferroni adjustment with a statistical significance p <  143 
0.0071 (0.05/7) was used. 144 
To assess the robustness of the primary analysis, we additionally conducted propensity score 145 
matching (PSM) as the sensitivity analysis. The propensity score was the predicted probability 146 
of being in the APT group given the values of all the aforementioned covariates. Each patient 147 
in the APT group was matched with a counterpart in the non-APT group. We adopted a greedy 148 
nearest neighbour algorithm and the caliper was set as 0.2 times the standard deviation of 149 
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the logit of propensity score [13]. The quality of matching was checked using the absolute 150 
standardized mean difference (ASMD) between the groups after matching, where a value less 151 
than 0.1 was considered to have a non-substantially difference between the groups [14]. Risks 152 
of in-hospital outcomes or time to event outcomes during a 6-month follow up between the 153 
APT and non-APT groups were compared using univariate logistic regression or univariate Cox 154 
model in which robust standard error was used to account for the outcome dependency 155 
within the same matching pairs. Additional adjustment of covariates due to possible 156 
imbalance of covariates was carried out when comparing the non-APT and different APT 157 
groups. Data analysis was conducted using SAS software version 9.4 (SAS Institute, Cary, NC). 158 
 159 
  160 
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Results 161 
Characteristics of study population 162 
After applying a series of exclusion criteria, a total of 97,355 patients with ICH were identified 163 
of whom 11,351 received APT and 86,004 received non-APT prior accident (Figure 1). Patients 164 
under APT treatment were divided into three groups according to the different types of APT 165 
prescribed before onset of ICH. Patients with APT treatment were either under COX-I (aspirin), 166 
ADP-I (clopidogrel or ticlopidine), or PGE-I (dipyridamole or cilostazol). The number of APT 167 
users were 8,282, 741 and 2,328 patients in the COX-I, ADP-I and PDE-I groups, respectively. 168 
Within the 86,004 ICH patients without APT, the mean age (± SD) was 61.4 (14.8) years, and 169 
64.4% were male (Table 1). However, the patients who received APT were generally older 170 
(mean age ± SD) in age (COX-I: 68.5 ± 12.1, ADP-1 71.8 ± 11.3, PDE-1: 70.0 ± 12.5), slightly 171 
more females, and had a substantial higher prevalence of many comorbidities than non-APT 172 
patients (Table 1). Among the 11,351 patients under APT, the patients received ADP-I were 173 
older than the other two groups (COX-I and PDE-I) (Table 1). Furthermore, the prevalence of 174 
hypertension, diabetes, dyslipidaemia, coronary artery disease, arterial fibrillation was 175 
substantially higher in the ADP-I group compared to other two APT groups. The PDE-I group 176 
had a higher prevalence of peripheral arterial disease than did the other two APT group. 177 
Furthermore, based on NIHSS, the severity of neurologic deficit was higher, and required 178 
surgical intervention after admission in the patients with prior ADP-I treatment compared to 179 
the other two groups (Table 1).  180 
Events during index hospitalization  181 
The event number and rate of various outcomes during index hospitalization in non-APT and 182 
different APT groups were studied (Supplemental Table 2). Patients under prior APT treatment 183 
had significantly higher in-hospital mortality rate than those without APT (odds ratio [OR], 184 
1.16; 95% confidence interval [CI], 1.09–1.23) when the covariates listed in Table 1 were 185 
adjusted (Table 2). In comparison with non-APT group, significantly higher in-hospital 186 
mortality was noted in patients that had received COX-I (OR, 1.17; 95% CI, 1.09–1.25) or ADP-187 
I (OR, 1.49; 95% CI, 1.24–1.79), but not with PDE-I (OR, 1.03; 95% CI, 0.91–1.16) (Table 2). 188 
Remarkably, the in-hospital mortality rate was significantly higher in the ADP-I group than in 189 
the PDE-I group (hazard ratio, 1.45; 95% CI, 1.17–1.80) (Table 2). Furthermore, a higher risk of 190 
in-hospital mortality was observed for the ADP-I group when compared to the COX-I group 191 
9 
 
 
(OR, 1.28; 95% CI, 1.06–1.54), but was not statistically significant (P = 0.012) after Bonferroni 192 
adjustment (Table 2). 193 
 In comparison to the non-APT group, patients with APT treatment appeared to have 194 
significantly higher risk to develop an ischemic stroke (OR, 1.18; 95% CI, 1.07–1.30) during 195 
hospitalization, especially those with COX-I treatment (OR, 1.17; 95% CI, 1.05–1.31) (Table 2). 196 
In addition, no significant difference in the risk of perioperative gastrointestinal bleeding 197 
among the groups was observed. 198 
Follow-up outcomes of ICH  199 
The event number and rate of various follow-up outcomes of ICH in each group were studied 200 
(Supplemental Table 2). No significant difference in risk of 6-month all-cause mortality was 201 
found between the APT and non-APT groups (Supplemental Table 2). Of note, the ADP-I group 202 
had a higher risk of mortaliy compared to the non-APT (hazard ratio [HR], 1.18; 95% CI, 1.05–203 
1.33], and a non-significant trend compared to COX-I (HR, 1.14; 95% CI, 1.01–1.29, p=0.037), 204 
and PDE-I (HR, 1.19; 95% CI, 1.04–1.37, p=0.011) after Bonferroni adjustment (Supplemental 205 
Table 3). In contrast, comparison of all four groups did not significantly show difference in the 206 
risk of new occurrence ischemic or haemorrhagic stroke during the six-month follow-up 207 
(Supplemental Table 3).  208 
 209 
Sensitivity analysis 210 
After PSM, the 11,285 patients in both APT and non-APT groups showed no significant 211 
difference (ASMD < 0.1)  in all the demographic and comorbidities such as gender, ages, 212 
morbidities, hospital level, patient income, or urbanization level (Table 3). Furthermore, the 213 
APT group did not received more surgical intervention compared to the non-APT group 214 
(Table 3). Baseline characteristics of ICH patients (Supplemental Table 4), and event number 215 
and rate (Supplemental Table 5) in the non-APT and difference APT groups were analysed. 216 
Comparison between all the groups showed no differences with in-hospital outcomes or 6-217 
months follow-up outcomes (Supplemental Table 4 & 5). The results of propensity score 218 
matching were less statistically significant due to the smaller sample size after matching 219 
(Table 4 and Supplemental Table 6). 220 
 221 
  222 
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Discussion 223 
Primary result 224 
Our study involving 22,702 ICH patients in Taiwan demonstrated significant increase in-225 
hospital mortality and adverse event at 6-months follow-up outcome in those ICH patients 226 
with prior APT compared to those without prior APT. Therefore, these results support the 227 
hypothesis that APT treatment prior ICH contribute to poor clinical outcome. However, the 228 
different types of prior APT treatment has various impact on the ICH patients’ poor outcome 229 
and mortality. 230 
 231 
Prior APT treatment associated with ICH 232 
Recently, APT treatment is often prescribed for both primary and secondary prevention of 233 
atherothrombotic vascular events, myocardial infarction, and vascular death. The correlation 234 
of prior APT treatment on ICH outcomes has been debated extensively based on inconsistent 235 
results. Some studies has demonstrated that APT plays a role in worsening of neurologic 236 
outcome and progression of haemorrhage size [15], but others have found that only combined 237 
APT contribute to poor clinical outcome [2]. It has been suggested that the differences in the 238 
outcomes could be associated with sample size, demographics, methodology, exclusion 239 
criteria and statistical analysis in study design [16]. However, we suggest there are two main 240 
possibilities that may explain the heterogeneous results across studies. First, the underlying 241 
disease in patients receiving APT, and second, the various mechanism of actions of the 242 
different APT. The mechanism of action for COX-I, such as aspirin is to irreversibly inhibit 243 
cyclooxygenase required for prostaglandin H2 formation, which promote blood clotting [17]. 244 
Another popular group of APT is the ADP-I, such as clopidogrel and ticlopidine, which 245 
irreversibly inhibits the P2Y12 subtype of ADP receptor, resulting in inhibition of platelet 246 
activation and fibrin cross-linking [18]. The third group of APT is the PDE-I, such as cilostazol 247 
and dipyridamole, which inhibit platelet aggregation due to increase cAMP via inhibition of 248 
phosphodiesterase [19]. Therefore, in our study, we minimized the risk of confounding by 249 
determining baseline characteristics of all ICH patients and using PSM to adjust for differences 250 
in the comparison groups. Furthermore, since different type of APT have different mechanism 251 
of action that may pose different level of ICH risk, we compared the clinical outcome among 252 
different types of APT. To date, this current study is the only national-base study, which 253 
analysis the risk of different types of prior APT used in ICH patients. 254 
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Several randomized studies have tried to determine if prehospital APT use is correlated with 255 
clinical outcome and ICH volume [6, 26]. In these studies, the use of any antiplatelet 256 
medication was considered as one research arm. However, it is unlikely that different 257 
antiplatelet medication with different mechanism of actions mentioned previously will have 258 
the same risk in ICH patients. Patients taking COX-I accounts for the largest group of APT user 259 
in previous studies. Another popular antiplatelet agent is ADP-I, which is often used in 260 
conjunction with COX-I, aspirin in patients with at high risk for ischemic events or patients 261 
with allergies or intolerances to aspirin [27]. Another group of APT is PDE-I, such as cilostazol 262 
or dipyridamole, which has been approved for use as a vasodilation antiplatelet drug. 263 
Cilostazol has been reported to be more effective than COX-I in the secondary prevention of 264 
all types of stroke, especially secondary haemorrhagic stroke in a clinical trial [31]. Also, a 265 
recent study also showed Cilostazol was non-inferior to aspirin for the prevention of 266 
cardiovascular events in patients with ischemic stroke [32].  267 
In our study, we assessed the effects of prior administration of various types of APT on 268 
patients with ICH, which yielded several important results. First, COX-I and ADP-I group, but 269 
not PDE-I group have significantly higher in-hospital mortality rate compared with non-APT 270 
group. These results appear to be consistent with those of clinical studies suggesting that ADP-271 
I is associated with poor neurologic outcome in ICH patients (refs).  The absence in poor 272 
outcome with PDE-I could be due to the additional beneficial effects of inhibiting the 273 
phosphodiesterase enzyme. Apart from blocking platelet aggregation, PDE-I can also inhibit 274 
cellular reuptake of adenosine into erythrocytes, resulting in an increase in extracellular 275 
adenosine [33]. Adenosine is clinically used in supraventricular tachycardia management and 276 
recently have been shown to have neuroprotective properties in stroke [34]. Second, our 277 
result also suggested the significant increased mortality risk is confined to patients receiving 278 
ADP-I treatment in comparison with COX-I and PDE-I groups. Recently, several studies have 279 
focus on the ADP-I effect on the intracranial haemorrhage. Wong and colleagues 280 
demonstrated higher rates of progression in patients on clopidogrel therapy in comparison 281 
with aspirin (COX-I) and warfarin (deplete vitamin K required for synthesis of active clotting 282 
factor) therapy [35]. Interestingly, aspirin exhibited more hematoma expansion and higher in-283 
hospital mortality rates at 3 months in one retrospective study [36]. Third, although overall 284 
mortality has no difference between APT and non-APT treatments during 6-months follow-up 285 
in our study, the ICH patients receiving prior ADP-I had significantly higher mortality rate than 286 
non-APT ICH patients. All these results appear to be consistent in suggesting that the ADP-I is 287 
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associated with a poor neurologic outcome in ICH patients. Although the reason for this is not 288 
known, a possible explanation is that platelet functional recovery is stable after COX-I is 289 
withdrawn for 5 days, but, there is variable platelet function recovery in patients with ADP-I 290 
treatment [37]. Fourth, a reduced mortality of survivors during the index hospitalization of 291 
prior COX-I treatment compared to the other groups was observed. This finding was 292 
unexpected and the reason for this is unknown. However, this could be due to COX-I have the 293 
additional benefits of anti-inflammation, analgesia and reduction in fever [38].  294 
 295 
Limitations 296 
We acknowledge that our study also has several limitations. First, the health insurance 297 
database that we used was developed for administrative purposes rather than from direct 298 
data collection. The NHIRD does not contain information of ICH details, such as severity, 299 
amount of bleeding, bleeding area, and size, which may bias the estimates. However, the CCI 300 
scores and estimated NIHSS were used to partially address this limitation. Second, the 301 
database only provided information on the frequency and classes of prescribed medications 302 
and did not provide detailed clinical information, so, we could only estimate the indication of 303 
drug administration. Third, the database did not contain information on various lifestyle risk 304 
factors for haemorrhagic stroke, such as physical activity, alcohol consumption, smoking, body 305 
mass index, socioeconomic status and diet, which could have a negative impact on the ICH 306 
were not included in the analysis. Although we adjusted the potential covariates, such as co-307 
morbidities and the use of other medications, the misclassification of these covariates could 308 
still have some impact on our results. Fifth, a majority of the patients were of Chinese origin 309 
in this study. The pharmacodynamics and pharmacokinetics of clopidogrel have interpatient 310 
variability related to ethic background, so this could limit their correlative value to non-311 
Chinese background patients [39]. 312 
 313 
 314 
Conclusion 315 
Our findings indicate that prior use of APT treatment is likely to be associated with higher in-316 
hospital mortality after ICH, especially patients under prior ADP-I, such as clopidogrel and 317 
ticlopidine treatment. Furthermore, in 6-months follow-up, prior ADP-I treatment significantly 318 
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increased over-all mortality in ICH patients. Our data suggest that the various effects observed 319 
are contributed by the various mechanism of actions of the antiplatelet agents. Future studies 320 
must address APT as individual drug types and not combine into a single entity. 321 
  322 
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Figure legends 323 
Figure 1  324 
Flow chart of the study patient selection. Patients with cerebrovascular accident admitted for 325 
hemorrhage stroke were included after relevant exclusions. After PSM 1:1 matching, patients 326 
without prior APT was selected. Spontaneous ICH patients receiving APT were further divided 327 
into three groups (COX-I, ADP-I, and PDE-I) according to the prior different medication 328 
treatment. 329 
Abbreviation: PSM, propensity score matching; APT, anti-platelet therapy; ICH, intracerebral 330 
hemorrhage; ADP-I, adenosine diphosphate receptor inhibitor; COX-I, irreversible 331 
cyclooxygenase inhibitor; PDE-I, phosphodiesterase inhibitor. 332 
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